Enhanced osteoblast development after continuous infusion of hPTH(1-84) in the rat.

Watson PH, Fraher LJ, Kisiel M, DeSousa D, Hendy G, Hodsman AB

Bone1 Feb 1999Cited by 22 (Europe PMC)

PMID9951775DOI10.1016/s8756-3282(98)00170-7PepBankPUB-09951775

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In rats, continuous rhPTH(1-84) at 0.1 microg/100 g did not significantly change pelvis sections versus vehicle.
In plain wordsIn rats, low-dose continuous rhPTH(1-84) did not significantly change pelvis tissue compared with vehicle.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changePelvis histology
Study
ratn: not reported in source
female Sprague-Dawley rat pelvis
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 microg/100 g body weight · subcutaneous continuous infusion · 7 daysAs given in this study (rat).
Source sentences
Summary
Sections of pelvis from rats continuously infused with 0.1 or 1 microg/100 g b.w. rhPTH(1-84) for 7 days did not differ significantly from those of the vehicle-treated controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats (12 weeks, 250 g) were randomly assigned to receive 0, 0.1, 1, or 5 microg/100 g body weight (b.w.) rhPTH(1-84) (0, 0.106, 1.06, or 5.305 nmol/kg) in vehicle (1% normal rat serum in saline) delivered by subcutaneous Alzet minipump.
Report a problemFND-0995177501
02AnimalAnimal study (in vivo)Mechanism
In rats, continuous rhPTH(1-84) at 1 microg/100 g did not significantly change pelvis sections versus vehicle.
In plain wordsIn rats, continuous rhPTH(1-84) did not significantly change pelvis tissue compared with vehicle at this dose.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changePelvis histology
Study
ratn: not reported in source
female Sprague-Dawley rat pelvis
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 microg/100 g body weight · subcutaneous continuous infusion · 7 daysAs given in this study (rat).
Source sentences
Summary
Sections of pelvis from rats continuously infused with 0.1 or 1 microg/100 g b.w. rhPTH(1-84) for 7 days did not differ significantly from those of the vehicle-treated controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats (12 weeks, 250 g) were randomly assigned to receive 0, 0.1, 1, or 5 microg/100 g body weight (b.w.) rhPTH(1-84) (0, 0.106, 1.06, or 5.305 nmol/kg) in vehicle (1% normal rat serum in saline) delivered by subcutaneous Alzet minipump.
Report a problemFND-0995177502
03AnimalAnimal study (in vivo)Mechanism
In rats, continuous rhPTH(1-84) increased cellular development with many layers of large osteoblasts around trabeculae versus vehicle.
In plain wordsIn rats, continuous rhPTH(1-84) increased bone-forming cell development compared with vehicle.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseOsteoblast development
Study
ratn: not reported in source
female Sprague-Dawley rat pelvis
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 microg/100 g body weight · subcutaneous continuous infusion · 7 daysAs given in this study (rat).
Source sentences
Summary
However, continuous infusion of 5 microg/100 g b.w. rhPTH(1-84) resulted in a dramatic increase in cellular development, with trabeculae surrounded by many layers of large, plump osteoblasts.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats (12 weeks, 250 g) were randomly assigned to receive 0, 0.1, 1, or 5 microg/100 g body weight (b.w.) rhPTH(1-84) (0, 0.106, 1.06, or 5.305 nmol/kg) in vehicle (1% normal rat serum in saline) delivered by subcutaneous Alzet minipump.
Report a problemFND-0995177503
04AnimalAnimal study (in vivo)Mechanism
In rats, pelvis osteoblasts stained positively for IGF-I during continuous rhPTH(1-84) at 0.1 microg/100 g.
In plain wordsIn rats, pelvis bone-forming cells showed IGF-I during low-dose continuous rhPTH(1-84).
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
Not applicableIGF-I staining
Study
ratn: not reported in source
female Sprague-Dawley rat pelvis
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 microg/100 g body weight · subcutaneous continuous infusion · 7 daysAs given in this study (rat).
Source sentences
Summary
All pelvis osteoblasts expressed osteocalcin, but only those from rats that received 0, 0.1, or 1 microg/100 g b.w. rhPTH(1-84) showed positive staining for IGF-I.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats (12 weeks, 250 g) were randomly assigned to receive 0, 0.1, 1, or 5 microg/100 g body weight (b.w.) rhPTH(1-84) (0, 0.106, 1.06, or 5.305 nmol/kg) in vehicle (1% normal rat serum in saline) delivered by subcutaneous Alzet minipump.
Report a problemFND-0995177504
05AnimalAnimal study (in vivo)Mechanism
In rats, pelvis osteoblasts stained positively for IGF-I during continuous rhPTH(1-84) at 1 microg/100 g.
In plain wordsIn rats, pelvis bone-forming cells showed IGF-I during continuous rhPTH(1-84) at this dose.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
Not applicableIGF-I staining
Study
ratn: not reported in source
female Sprague-Dawley rat pelvis
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 microg/100 g body weight · subcutaneous continuous infusion · 7 daysAs given in this study (rat).
Source sentences
Summary
All pelvis osteoblasts expressed osteocalcin, but only those from rats that received 0, 0.1, or 1 microg/100 g b.w. rhPTH(1-84) showed positive staining for IGF-I.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats (12 weeks, 250 g) were randomly assigned to receive 0, 0.1, 1, or 5 microg/100 g body weight (b.w.) rhPTH(1-84) (0, 0.106, 1.06, or 5.305 nmol/kg) in vehicle (1% normal rat serum in saline) delivered by subcutaneous Alzet minipump.
Report a problemFND-0995177505
06AnimalAnimal study (in vivo)Mechanism
In rats, abundant osteoblasts during high-dose continuous rhPTH(1-84) lacked IGF-I staining, unlike vehicle-treated osteoblasts.
In plain wordsIn rats, high-dose continuous rhPTH(1-84) produced bone-forming cells without IGF-I staining, unlike vehicle.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseIGF-I staining
Study
ratn: not reported in source
female Sprague-Dawley rat pelvis
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 microg/100 g body weight · subcutaneous continuous infusion · 7 daysAs given in this study (rat).
Source sentences
Summary
The extra-abundant osteoblasts from rats that received 5 microg/100 g b.w. rhPTH(1-84) did not stain for IGF-I.
2 context sentences(design, population, supporting numbers)
Summary · context
All pelvis osteoblasts expressed osteocalcin, but only those from rats that received 0, 0.1, or 1 microg/100 g b.w. rhPTH(1-84) showed positive staining for IGF-I.
Summary · context
Female Sprague-Dawley rats (12 weeks, 250 g) were randomly assigned to receive 0, 0.1, 1, or 5 microg/100 g body weight (b.w.) rhPTH(1-84) (0, 0.106, 1.06, or 5.305 nmol/kg) in vehicle (1% normal rat serum in saline) delivered by subcutaneous Alzet minipump.
Report a problemFND-0995177506
07AnimalAnimal study (in vivo)Mechanism
In rats, osteoblast IGFBP-3, -4, and -5 staining increased with continuous rhPTH(1-84) dose and osteoblast number.
In plain wordsIn rats, staining for three IGF-binding proteins increased with continuous rhPTH(1-84) dose and bone-forming cell number.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseIGFBP staining
Study
ratn: not reported in source
female Sprague-Dawley rat pelvis
Comparator
lower rhPTH(1-84) doses
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous continuous infusion · 7 daysAs given in this study (rat).
Source sentences
Summary
However, although all osteoblasts stained positively for IGF binding proteins (IGFBPs)-3, -4, and -5, staining for these IGFBPs increased as the dose of rhPTH(1-84) (and osteoblast number) increased.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats (12 weeks, 250 g) were randomly assigned to receive 0, 0.1, 1, or 5 microg/100 g body weight (b.w.) rhPTH(1-84) (0, 0.106, 1.06, or 5.305 nmol/kg) in vehicle (1% normal rat serum in saline) delivered by subcutaneous Alzet minipump.
Report a problemFND-0995177507
08AnimalAnimal study (in vivo)Mechanism
In rats, osteoblasts lacked IGF-I staining with continuous rhPTH(1-84) at 5 microg/100 g, unlike the positive staining at 0.1 microg/100 g.
In plain wordsIn rats, bone-forming cells lacked IGF-I staining during high-dose continuous rhPTH(1-84), unlike cells during the lower dose.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseIGF-I staining versus lower-dose PTH
Study
ratn: not reported in source
female Sprague-Dawley rat pelvis
Comparator
rhPTH(1-84) at 0.1 microg/100 g body weight
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 microg/100 g body weight · subcutaneous continuous infusion · 7 daysAs given in this study (rat).
Source sentences
Summary
The extra-abundant osteoblasts from rats that received 5 microg/100 g b.w. rhPTH(1-84) did not stain for IGF-I.
2 context sentences(design, population, supporting numbers)
Summary · context
All pelvis osteoblasts expressed osteocalcin, but only those from rats that received 0, 0.1, or 1 microg/100 g b.w. rhPTH(1-84) showed positive staining for IGF-I.
Summary · context
Female Sprague-Dawley rats (12 weeks, 250 g) were randomly assigned to receive 0, 0.1, 1, or 5 microg/100 g body weight (b.w.) rhPTH(1-84) (0, 0.106, 1.06, or 5.305 nmol/kg) in vehicle (1% normal rat serum in saline) delivered by subcutaneous Alzet minipump.
Report a problemFND-0995177508
09AnimalAnimal study (in vivo)Mechanism
In rats, osteoblasts lacked IGF-I staining with continuous rhPTH(1-84) at 5 microg/100 g, unlike the positive staining at 1 microg/100 g.
In plain wordsIn rats, bone-forming cells lacked IGF-I staining during high-dose continuous rhPTH(1-84), unlike cells during the lower dose.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseIGF-I staining versus lower-dose PTH
Study
ratn: not reported in source
female Sprague-Dawley rat pelvis
Comparator
rhPTH(1-84) at 1 microg/100 g body weight
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 microg/100 g body weight · subcutaneous continuous infusion · 7 daysAs given in this study (rat).
Source sentences
Summary
The extra-abundant osteoblasts from rats that received 5 microg/100 g b.w. rhPTH(1-84) did not stain for IGF-I.
2 context sentences(design, population, supporting numbers)
Summary · context
All pelvis osteoblasts expressed osteocalcin, but only those from rats that received 0, 0.1, or 1 microg/100 g b.w. rhPTH(1-84) showed positive staining for IGF-I.
Summary · context
Female Sprague-Dawley rats (12 weeks, 250 g) were randomly assigned to receive 0, 0.1, 1, or 5 microg/100 g body weight (b.w.) rhPTH(1-84) (0, 0.106, 1.06, or 5.305 nmol/kg) in vehicle (1% normal rat serum in saline) delivered by subcutaneous Alzet minipump.
Report a problemFND-0995177509

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.